Epithelial-Mesenchymal Transition (EMT) Explained: What It Does and When to Use It

EMT markers are the molecular evidence that an epithelial cell has begun the epithelial-mesenchymal transition (EMT): a reversible program in which a stationary, tightly joined epithelial cell loses its junctions and polarity and becomes a motile, invasive mesenchymal-like cell. EMT sits at the center of metastasis, fibrosis and drug-resistance research, and this guide covers the EMT pathway, the epithelial cell markers and mesenchymal markers that define each state, the EMT transcription factors that drive the switch, and how to build a marker panel that actually proves a transition happened.

Epithelial-Mesenchymal Transition: Two Cell States, One Program

Epithelial-mesenchymal transition is a reversible cellular program in which epithelial cells lose their apical-basal polarity and cell-cell junctions and gain the migratory, invasive properties of mesenchymal cells (Kalluri & Weinberg, J Clin Invest 2009). The reverse process, mesenchymal-epithelial transition (MET), restores the epithelial state.

The two states are defined by opposing molecular equipment. Epithelial cells are held in sheets by E-cadherin-based adherens junctions, tight junctions and desmosomes, with a cytokeratin intermediate-filament network. Mesenchymal cells trade those junctions for N-cadherin, rebuild their cytoskeleton around vimentin, remodel the extracellular matrix, and move.

Three contexts use the same core program (Zeisberg & Neilson, J Clin Invest 2009). Type 1 EMT drives embryonic development (gastrulation, neural crest migration). Type 2 EMT operates in wound healing and, when it fails to switch off, in organ fibrosis. Type 3 EMT is the version cancer biologists study: carcinoma cells reactivate the program to invade, enter the circulation and seed metastases.

One point matters for experimental design more than any other: EMT is rarely all-or-nothing. Most cells in tumors and fibrotic tissue occupy partial (hybrid) EMT states, co-expressing epithelial and mesenchymal markers at the same time (Yang et al., Nat Rev Mol Cell Biol 2020). This is why single-marker readouts fail, and why the consensus guidelines call for combined marker panels plus a functional readout.

✕ Close

The EMT Pathway: From Extracellular Signal to Transcriptional Switch

The EMT pathway is not a single cascade but a set of converging inputs that all funnel into a small group of master transcription factors. The logic runs in three tiers.

1. Inducing signals. TGF-β is the canonical and most widely used EMT inducer, signaling through SMAD2/3-SMAD4 as well as non-SMAD arms (PI3K/AKT, MAPK, RhoA) (Lamouille et al., Nat Rev Mol Cell Biol 2014). Wnt/β-catenin, Notch, Hedgehog, receptor tyrosine kinase ligands (EGF, FGF, HGF), hypoxia (HIF-1α) and inflammatory cytokines feed the same program, and in real tissue usually act in combination.
2. EMT transcription factors (EMT-TFs). The signals converge on Snail (SNAI1), Slug (SNAI2), ZEB1/ZEB2 and Twist1. These repress the CDH1 (E-cadherin) gene and epithelial junction genes while activating mesenchymal genes. They cross-regulate each other, and the ZEB1/miR-200 double-negative feedback loop acts as the bistable switch that stabilizes epithelial, hybrid or mesenchymal states (Brabletz et al., Nat Rev Cancer 2018).
3. Phenotypic execution. Junctions disassemble, the cadherin switch occurs, the cytoskeleton is rebuilt on vimentin, matrix metalloproteinases degrade basement membrane, and the cell acquires motility and invasiveness — the properties measured in migration, invasion and wound-healing assays.

✕ Close

Practical consequence: in cell culture, 5–10 ng/mL recombinant TGF-β1 for 48–72 h is the standard positive-control induction for EMT marker validation in responsive epithelial lines (A549, MCF10A and NMuMG are common choices).

EMT Markers: Epithelial Cell Markers, Mesenchymal Markers and EMT Transcription Factors

EMT markers fall into three functional classes: epithelial markers that should go down, mesenchymal markers that should go up, and the transcription factors that drive the change. A defensible EMT claim samples all three.

Epithelial cell markers (expect ↓)

Loss of these defines the exit from the epithelial state. E-cadherin (CDH1) is the anchor of the class — the adherens junction protein whose transcriptional repression by Snail and ZEB1 is the defining molecular event of EMT. Supporting epithelial cell markers include the tight-junction proteins ZO-1, claudins and occludin, the intermediate filaments cytokeratin 8/18/19, and the surface antigen EpCAM.

Watch for: loss of E-cadherin at the membrane matters as much as total protein level. Immunofluorescence localization catches junctional disassembly and internalization that a whole-lysate western blot can miss.

Example BioHippo reagents: E-Cadherin Antibody / CDH1 (WB/IF, NSJ Bioreagents RQ5389) · Human E-Cadherin/CDH1 ELISA Kit PicoKine® (quantification, Boster Bio EK0561).

Mesenchymal markers (expect ↑)

Gain of these defines entry into the mesenchymal state. Vimentin is the most widely used mesenchymal marker — the intermediate filament that replaces the cytokeratin network and correlates tightly with migratory capacity. N-cadherin (CDH2) is its junctional counterpart, the gain side of the cadherin switch. Fibronectin reports matrix remodeling; α-SMA flags the myofibroblast phenotype central to fibrosis (type 2) EMT; MMP-2/MMP-9 mark invasive capacity.

Watch for: vimentin alone is not proof of EMT. Fibroblasts, endothelial cells and immune cells in any tissue or mixed culture are constitutively vimentin-positive. Pair it with epithelial marker loss in the same cells, ideally by co-staining.

Example BioHippo reagents: Anti-VIM/Vimentin Polyclonal Antibody (AtaGenix HY550014) · N-Cadherin Antibody / CDH2 / CD325 (NSJ Bioreagents R30391) · Human Vimentin, VIM ELISA Kit (Bioassay Technology Laboratory E1673Hu).

✕ Close

EMT transcription factors (the drivers)

Snail (SNAI1) and Slug (SNAI2) are the immediate-early repressors of CDH1; ZEB1/ZEB2 sustain and lock in the mesenchymal state through the miR-200 feedback loop; Twist1 is prominent in developmental and metastatic contexts. Their induction typically precedes surface-marker changes, which makes them the earliest detectable evidence of EMT — often visible by qPCR or western blot within hours of TGF-β treatment, before the cadherin switch is measurable.

Watch for: EMT-TFs are low-abundance nuclear proteins with short half-lives. Use nuclear-enriched lysates for western blot, validate antibodies against an induced positive control (see our antibody validation guide), and treat qPCR as the more sensitive first-pass readout.

Example BioHippo reagents: Anti-SNAIL/SNAI1 Antibody Picoband® (Boster Bio A00716-2) · SLUG Antibody / SNAI2 (NSJ Bioreagents R31818) · ZEB1 Antibody (NSJ Bioreagents R35719) · TWIST1/2 Antibody (NSJ Bioreagents RQ7509).

EMT marker reference table

When to Use EMT Analysis: Cancer, Fibrosis, Development and Wound Healing

Cancer metastasis and invasion

EMT analysis is standard whenever the question involves how carcinoma cells acquire invasiveness: comparing primary tumors with metastases, characterizing invasive fronts, profiling circulating tumor cells (which are frequently EpCAM-low, hybrid-state cells), or testing whether a gene or compound of interest changes invasive behavior. Marker panels are paired with transwell invasion or migration assays so the molecular and functional readouts support each other (Yang et al., 2020). Browse cancer research reagents for marker antibodies, ELISA kits and cell models.

Drug resistance and cancer stemness

EMT is repeatedly linked to chemotherapy and targeted-therapy resistance and to stem-like tumor cell states (Dongre & Weinberg, Nat Rev Mol Cell Biol 2019). If a resistant derivative line has emerged in your lab, an EMT marker panel (E-cadherin down, vimentin/ZEB1 up) is one of the first characterizations worth running — EMT-TF expression in resistant clones can explain the phenotype and suggest reversal strategies.

Fibrosis

In kidney, liver, lung and cardiac fibrosis research, type 2 EMT contributes to the myofibroblast pool that deposits pathological matrix. The panel shifts accordingly: α-SMA, fibronectin and collagen readouts join the core E-cadherin/vimentin pair, and TGF-β1 is both the disease-relevant stimulus and the standard in vitro model. Matrix and adhesion reagents are grouped in the ECM & Cell Adhesion collection.

Development and differentiation

Gastrulation, neural crest delamination and organogenesis all run on type 1 EMT, and stem cell differentiation protocols use EMT/MET marker panels to track lineage transitions — including the MET step required for iPSC reprogramming.

Wound healing and regeneration

Re-epithelialization uses a controlled partial EMT: keratinocytes at the wound edge loosen junctions and migrate while retaining epithelial identity, typically with Slug rather than full mesenchymal conversion. Marker panels here are designed to detect intermediate states, not endpoints.

✕ Close

How to Build an EMT Marker Panel That Proves a Transition

Consensus guidelines from the EMT International Association are direct on this point: EMT should not be claimed from a single marker, and molecular data should be paired with evidence of changed cell behavior (Yang et al., 2020). A minimal defensible design looks like this.

1. Pick at least one marker per class. The standard core panel is E-cadherin (epithelial, down), N-cadherin + vimentin (mesenchymal, up), and Snail or ZEB1 (EMT-TF, up). Add context markers as needed: α-SMA for fibrosis, EpCAM for sorting, claudins/ZO-1 for junction integrity.
2. Measure at both protein and transcript level. qPCR (CDH1, CDH2, VIM, SNAI1, ZEB1) catches early transcriptional changes; western blot confirms protein; IF/ICC adds the localization information that distinguishes junctional loss from expression loss; flow cytometry (E-cadherin/EpCAM vs. vimentin/N-cadherin) quantifies state distributions cell by cell — the only way to see the hybrid subpopulations that population averages hide.
3. Include a validated positive control. TGF-β1-treated responsive cells (48–72 h) provide the reference shift for antibody validation and effect-size calibration. Untreated parallel cultures anchor the baseline.
4. Add a functional readout. Wound-healing (scratch), transwell migration or Matrigel invasion assays convert a marker shift into the phenotype the markers are supposed to predict. Marker change without behavioral change is a hybrid state, not completed EMT — worth reporting, but as what it is.

Timing matters: EMT-TF induction (hours) precedes the cadherin switch (days). A single endpoint can miss the program entirely; a 0/24/48/72 h series rarely does.

✕ Close

EMT Marker Reagents at BioHippo: Ordering Information

Representative reagents from the BioHippo catalog for each arm of an EMT panel — antibodies for WB/IF/flow, ELISA kits for quantification, and recombinant TGF-β1 for induction models.

Species-matched variants (mouse, rat and others) of most kits above are available in the catalog; search by marker name at ebiohippo.com. Need a marker that is not listed, or a bulk quote for a full panel? Request a quote.

EMT Markers FAQ

What are the most reliable EMT markers?

The most widely accepted core set is E-cadherin (loss), N-cadherin and vimentin (gain), and one or more EMT transcription factors — Snail, Slug, ZEB1 or Twist1. Reliability comes from the combination, not any single marker: current guidelines require changes in several markers from different classes, plus a functional change in cell behavior, before EMT is claimed.

What is the difference between epithelial cell markers and mesenchymal markers?

Epithelial cell markers (E-cadherin, cytokeratins, EpCAM, ZO-1, claudins, occludin) report the junctional, polarized, sheet-forming state and decrease during EMT. Mesenchymal markers (N-cadherin, vimentin, fibronectin, α-SMA) report the motile, matrix-remodeling state and increase. The informative result is the reciprocal shift measured in the same cells.

Is vimentin expression enough to prove EMT?

No. Fibroblasts, endothelial cells and leukocytes express vimentin constitutively, so vimentin positivity in tissue or mixed cultures can simply mean stromal cells are present. Proof requires vimentin gain together with epithelial marker loss in cells of confirmed epithelial origin — co-staining or lineage tracing settles it.

What is the cadherin switch?

The replacement of E-cadherin by N-cadherin at the cell surface during EMT. E-cadherin loss dissolves stable epithelial junctions; N-cadherin gain favors weaker, more dynamic contacts and interaction with stromal cells, supporting migration and invasion. Because it involves one marker falling as the other rises, it is the single most interpretable two-marker readout in the field.

Which EMT pathway should be targeted to induce or block EMT in vitro?

TGF-β1 is the standard inducer — 5–10 ng/mL for 48–72 h in a responsive epithelial line produces a robust, well-characterized transition. To block or reverse EMT, TGF-β receptor kinase inhibitors and EMT-TF knockdown (SNAI1, ZEB1) are the most common approaches; which is appropriate depends on whether the question concerns induction, maintenance or reversal of the state.

How is partial EMT detected?

By single-cell methods. Flow cytometry with an epithelial marker (E-cadherin or EpCAM) on one axis and a mesenchymal marker (vimentin or N-cadherin) on the other resolves double-positive hybrid populations directly; co-immunofluorescence does the same in situ. Bulk lysate methods average the states together and cannot distinguish a hybrid population from a mixture of pure states.

Which EMT markers work best for western blot versus flow cytometry?

Western blot suits total-protein comparisons of E-cadherin, N-cadherin and vimentin across a time course, and nuclear-enriched lysates for Snail, Slug, ZEB1 and Twist1. Flow cytometry is the better choice when the question is which cells changed: surface E-cadherin or EpCAM against intracellular vimentin or N-cadherin resolves epithelial, hybrid and mesenchymal fractions in one run. Use the same antibody clones across methods where possible so the readouts can be compared.

References

1. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119(6):1420–1428. PMID 19487818
2. Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest. 2009;119(6):1429–1437. PMID 19487819
3. Yang J, Antin P, Berx G, et al. Guidelines and definitions for research on epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2020;21(6):341–352. PMID 32300252
4. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15(3):178–196. PMID 24556840
5. Brabletz T, Kalluri R, Nieto MA, Weinberg RA. EMT in cancer. Nat Rev Cancer. 2018;18(2):128–134. PMID 29326430
6. Dongre A, Weinberg RA. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2019;20(2):69–84. PMID 30459476

For research use only. Not for diagnostic or therapeutic use.